Fresh evidence has emerged of cannabis medicine’s potential in reducing nausea and vomiting caused by chemotherapy.
A world-first clinical trial in Australia tested a product supplied by Tilray, the cannabis research, cultivation, production, and distribution company.
Results published in Annals of Oncology found a significant improvement in the control of chemotherapy-induced nausea and vomiting.
A quarter of the patients taking medicinal cannabis experienced no vomiting and nausea, compared to 14 per cent of people who took a placebo.
The pilot phase of the study ran for two-and-a-half years with 81 participants enrolled.
To be included in the study, patients had to have already experienced nausea and vomiting during chemotherapy despite having taken nausea prevention medication.
Philippe Lucas, vice president of global patient research and access at Tilray, said: “The side-effects associated with chemotherapy are some of the primary causes of treatment discontinuation, so improving the control of nausea and vomiting can not only improve the quality of life of patients, by allowing those affected by cancer to complete their treatment it can also potentially save lives.”
Peter Grimison, medical oncologist at Chris O’Brien Lifehouse and associate professor at the University of Sydney, said: “Nausea and vomiting are among the most distressing and feared consequences of chemotherapy.
“These encouraging results indicate medicinal cannabis can help improve quality of life for chemotherapy patients.”
Side effects such as sedation, dizziness and drowsiness were rated as moderate to severe in about one third of people using medicinal cannabis, but these are considered manageable according to the researchers.
Professor Grimison said: “The trial will now move to a larger phase to determine with much more certainty how effective medicinal cannabis is and whether it should be considered for use in routine cancer care. The next phase of the trial is ongoing and will recruit an extra 170 people.”
The world’s largest trial of medical cannabis at the time it launched, the CannabisCINV study is a collaboration between Chris O’Brien Lifehouse, the University of Sydney, the NHMRC Clinical Trials Centre and leading New South Wales (NSW) cancer centres.
Tilray is supplying the product for the trial, which is being funded by the NSW government.
Beckham-backed cannabis brand floats on LSE
A UK cannabis company, backed by David Beckham, has been valued in excess of £25 million in its first day trading on the London stock market.
UK-based Cellular Goods has become the first provider of consumer products based on biosynthetic cannabinoids to join the London stock market.
The company has been admitted to the Official List following a significantly oversubscribed initial public offering that raised £13 million before expenses.
More than 6,000 valid applications for shares were received in respect of the IPO.
Shares will commence trading on the main market of the LSE from 8am on Friday 26 February, under the ticker symbol CBX.
A total of 260,000,000 ordinary shares have been issued at five pence each to institutional and retail investors, valuing Cellular Goods at a market capitalisation in excess of £25 million.
Cellular Goods was established in August 2018 to develop efficacy-led and research-backed cannabinoid products.
The initial focus is on premium skincare and topical athletic recovery products to be launched from this autumn.
Earlier this month it was revealed that former England footballer, David Beckham’s investment firm, DB Ventures had bought a stake in the company.
The purpose of the flotation on the LSE is to raise the public profile and provide new funds for the company’s expansion and long-term growth.
“Cellular Goods’ debut on the London Stock Exchange is a major step in the company’s development and provides a strong foundation to execute our long-term growth strategy,”commented Alexis Abraham, chief executive officer
“We are delighted with the strong support from a wide range of institutional and retail investors to build premium consumer products based on biosynthetic cannabinoids under the Cellular Goods brand.”
First study of cannabis in veterans with PTSD
The first observational study to determine the efficacy of cannabis for veterans with PTSD has gained approval from regulators in the US.
US charity, The Battle Brothers Foundation has received approval to launch an observational study on the use of medical cannabis to help combat PTSD in veterans.
The two groups received approval to proceed with the study from the national Independent Review Board (IRB), the independent committee that reviews the methods proposed for research to ensure that they are ethical.
“This news could not come at a better time,” Bryan Buckley, founder and president of the board for Battle Brothers Foundation.
“Every day, 22 veterans are dying due to effects of post-traumatic stress from opioid addiction to depression. Through anecdotal experiences, we know that cannabis can alleviate symptoms and provide relief.
“We appreciate that the IRB recognises the validity of and the need for this study.”
According to the National Institutes of Health, the rate of PTSD among returning service members varies widely across wars and eras.
In one major study of 60,000 Iraq and Afghanistan veterans, 13.5 percent of deployed and non-deployed veterans screened positive for PTSD, while other studies show the rate to be as high as 20 to 30 percent.
As many as 500,000 US troops who served in these wars over the past 13 years have been diagnosed with PTSD.
The study will enroll 60 California veterans, with moderate or severe PTSD over the next year.
Participants will dose and titrate individually purchased products under their own discretion and will be followed for 90 days to evaluate the safety and efficiency of cannabis on their symptoms.
Results of the study will be documented and monitored at that time.
The Battle Brothers Foundation is the nonprofit arm of Helmand Valley Growers Company (HVGC), a cannabis company founded by disabled United States Special Operations veterans that donates 100 percent of its profits to fund research on the medical use of cannabis for veterans.
Can CBD improve your fitness?
The market is full of products which promise weight loss, muscle gain and recovery benefits, with glowing endorsements from all kinds of sportspeople. Here we explore what CBD has to offer.
From reducing risks of conditions such as heart disease to improving overall mood, getting the right amount and right kind of exercise provides numerous benefits for both physical and mental health.
With the likes of gyms, leisure centres and exercise classes closed due to the Covid-19 pandemic, many of us have resorted to home workouts for the first time and are looking for the perfect supplement to aid these sessions – could CBD be the one?
One of the most popular reasons for using CBD as part of your exercise routine is the effect it has on recovery and pain relief. Whether you’re suffering from a slight niggle or a long-term injury, the remedy has been proven to speed recovery and fight fatigue, with one study finding that by reducing oxidative damage – which is caused by physical stress – CBD can help us recover faster and perform better.
Topical CBD products such as creams can be particularly beneficial to those who are prone to joint pain, by providing highly targeted relief to ensure that those unavoidable twinges don’t negatively impact your overall workout.
In addition, CBD may also be effective in relieving muscular aches and soreness thanks to its anti-inflammatory properties. A 2009 study into the effects of cannabinoids on the body found that they can suppress inflammatory response, leading to less tension in the area and, in turn, less of a break needed between your workouts.
One of the biggest pre-workout struggles is building enough motivation and momentum to get started and keep your routine going. While it hasn’t been shown to be a performance-enhancing product, the research into CBD’s effect on areas such as mental health and sleep quality leads us to believe that it can be a great supplement for breaking down mental barriers.
Several studies have linked CBD to overall improvement in mood, while it has also been well documented that the remedy can effectively ease symptoms of depression thanks to its positive effect on serotonin receptors in the brain. While CBD doesn’t necessarily boost these levels, its impact on the brain’s receptors may affect how we respond to the serotonin already in our systems.
Research backs up these claims, with a 2014 animal study finding that CBD’s effect on the receptors produced both antidepressant and anti-anxiety effects – both of which can be extremely helpful when gathering motivation to exercise.
Too tired for a workout? A review of studies in 2017 found that CBD “may have therapeutic potential for the treatment of insomnia”, meaning it’s likely to improve sleep quality, allowing us to wake up feeling refreshed and ready to take on a workout.
While research into certain areas is still ongoing, and it’s worth noting that effects will depend on external factors such as dosage, it would appear that CBD has several pre- and post-workout benefits.
News7 months ago
NHS lines up cannabis medicine manufacturing
News3 months ago
Community extends support to cannabis icon Rick Simpson
Case Studies11 months ago
CBD oil and fibromyalgia – a case study
Feature8 months ago
Medical cannabis could help long-term effects of COVID-19, says David Nutt
Insight5 months ago
I’ve gone from a wheelchair to walking thanks to cannabis
News5 months ago
“I’m not a bad person” – chronically ill woman convicted of growing medical cannabis
News5 months ago
Cancer survivor claims cannabis oil helped her beat brain tumour
News5 months ago
Mum of three-year-old with ‘one in a million’ condition fights for medical cannabis funding